SCHEMBL3044022

SCHEMBL3044022

O=C1CCC(=O)N1c1c[nH]c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 4/20 0.43
MAPT P10636 4/20 0.43
LMNA P02545 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 1/20 0.43
SIRT2 Q8IXJ6 2/20 0.42
SIRT1 Q96EB6 1/20 0.42
PRKD3 O94806 1/20 0.42
CCNB2 O95067 1/20 0.42
CCNE2 O96020 1/20 0.42
ABL1 P00519 1/20 0.42
PRKCG P05129 1/20 0.42
PRKCB P05771 1/20 0.42
CDK1 P06493 1/20 0.42
PIM1 P11309 1/20 0.42
CDK4 P11802 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30688235 1.00 SMN1; SMN2 (0.43) SMN1; SMN2RAB9AKDM4EMAPTLMNA
SCHEMBL31727125 0.93 SMN1; SMN2 (0.48) SMN1; SMN2RAB9AKDM4EMAPTLMNA
SCHEMBL856333 0.80 TLR9 (0.52) MAPTMEN1KMT2ASIRT2SIRT1
SCHEMBL28167164 0.79 SIRT2 (0.41) SMN1; SMN2RAB9AKDM4EMAPTLMNA
SCHEMBL28841040 0.77 ADRB1 (0.53) MAPTMEN1KMT2AHTR6DRD2
SCHEMBL20995833 0.77 SMN1; SMN2 (0.49) SMN1; SMN2RAB9AKDM4EMAPTLMNA
SCHEMBL21047718 0.76 BCHE (0.42) SMN1; SMN2RAB9AKDM4EMAPTLMNA
SCHEMBL29117052 0.76 RAB9A (0.54) SMN1; SMN2RAB9AKDM4EMAPTLMNA
SCHEMBL21047574 0.73 CYP2A6 (0.41) SMN1; SMN2RAB9AKDM4EMAPTLMNA
SCHEMBL3060875 0.73 KMT2A (0.47) KMT2APIM1PRKCQGPR84DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102702175-B Preparation method of indole-3-succinimide UNIV DONGHUA 2014-08-13 CN claimed
CN-102702175-A Preparation method of indole-3-succinimide UNIV DONGHUA 2012-10-03 CN claimed
US-20240091202-A1 COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS UNIVERSITÄT BASEL (CH) 2024-03-21 US disclosed
EP-4301358-A2 COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS Universität Basel Vizerektorat Forschung (CH) 2024-01-10 EP disclosed
CN-117295521-A Compositions for treating EBV-associated diseases or conditions 巴塞尔大学 2023-12-26 CN disclosed
WO-2022184930-A2 COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS UNIVERSITÄT BASEL (CH) 2022-09-09 WO disclosed
EP-4052705-A1 COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS Universität Basel Vizerektorat Forschung (CH) 2022-09-07 EP disclosed
CN-108264503-A A kind of preparation method of 3- Indolylmaleimide compounds 东华大学 2018-07-10 CN disclosed
CN-105153126-A Preparation method of bisindolyl maleimide compounds NAT UNIV DONG HWA 2015-12-16 CN disclosed
CN-102702175-B Preparation method of indole-3-succinimide UNIV DONGHUA 2014-08-13 CN disclosed
CN-102702175-B Preparation method of indole-3-succinimide UNIV DONGHUA 2014-08-13 CN disclosed
CN-102702175-B Preparation method of indole-3-succinimide UNIV DONGHUA 2014-08-13 CN disclosed
CN-102942560-A Preparation method of 3-(2-methylindolyl-3-)pyrryl-2,5-dione UNIV DONGHUA 2013-02-27 CN disclosed
US-8377927-B2 Compositions and methods for treatment of cancer ARQULE, INC. (US) 2013-02-19 US disclosed
CN-102702175-A Preparation method of indole-3-succinimide UNIV DONGHUA 2012-10-03 CN disclosed
CN-102702175-A Preparation method of indole-3-succinimide UNIV DONGHUA 2012-10-03 CN disclosed
CN-102702175-A Preparation method of indole-3-succinimide UNIV DONGHUA 2012-10-03 CN disclosed
US-20100221251-A1 Compositions and Methods for Treatment of Cancer ARQULE, INC. (US) 2010-09-02 US disclosed
EP-0477844-B1 Indole compounds and their use ORIENT CHEMICAL IND (JP) 1997-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221251-A1 Compositions and Methods for Treatment of Cancer PDCD5, TP53, NUP205 SMN1; SMN2 2087/4885RAB9A 2218/4885KDM4E 728/4885
US-20240091202-A1 COMPOSITIONS FOR THE TREATMENT OF EBV ASSOCIATED DISEASES OR CONDITIONS IDO1, IDO2, MALT1 SMN1; SMN2 4220/4885RAB9A 4159/4885KDM4E 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.